



Corrigendum

Corrigendum to “Synthesis and structure–activity relationships of *N*-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists” [Bioorg. Med. Chem. 16 (2008) 144–156]


Ippei Sato^{a,*}, Koichiro Morihira^a, Hiroshi Inami^a, Hirokazu Kubota^a, Tatsuaki Morokata^a, Keiko Suzuki^a, Noritaka Hamada^a, Yosuke Iura^b, Aiko Nitta^b, Takayuki Imaoka^b, Toshiya Takahashi^b, Makoto Takeuchi^a, Mitsuaki Ohta^a, Shin-ichi Tsukamoto^a

^a Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan

^b Pharmaceutical Research Laboratories, Toray Industries Inc., 6-10-1 Tebiri, Kamakura, Kanagawa 248-8555, Japan

The authors regret that this article contains six errors in nomenclature.

1. In Scheme 7, all instances of “*exo*-isomer” should be changed to “*endo*-isomer,” and all instances of “*endo*-isomer” should be changed to “*exo*-isomer.” The corrected scheme is shown here.



Scheme 7.

2. In the abstract, in line 6, “*N*-” should be changed to “*exo-N*-.”
3. On page 147, left-hand column, in lines 9 and 10, “*exo*-derivative (30)” should be changed to “*endo*-derivative (30).”
4. On page 147, left-hand column, in line 10, “*endo*-derivative (31)” should be changed to “*exo*-derivative (31).”
5. On page 147, right-hand column, in line 6, “*endo*-isomer” should be changed to “*exo*-isomer.”
6. On page 154, right-hand column, in Section 5.1.33, “*endo*” should be changed to “*exo*.”

DOI of original article: [10.1016/j.bmc.2007.10.003](https://doi.org/10.1016/j.bmc.2007.10.003).

* Corresponding author. Tel.: +81 29 863 6732; fax: +81 29 852 5387.

E-mail address: ippei.sato@jp.astellas.com (I. Sato).